Genetic testing for familial cancer: Consequences of ret proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2

Archives of Surgery

Volumn 132, Issue 9, 1997, Pages 1022-1025

  Learoyd, Diana L ^a,b   Marsh, Debbie J ^a   Richardson, Anne Louise ^a   Twigg, Stephen M ^a,b   Delbridge, Leigh ^b   Robinson, Bruce G ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHILD; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0030884903     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430330088015     Document Type: Article

References (27)

1. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363: 458-460.
2. Donis-Keller H, Don S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851-856.
3. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994; 6:70-74.
4. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA. 1996;276: 1575-1579.
5. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlations in MEN 2: report of the International RET Mutation Consortium. J Intern Med. 1995;238:343-346.
6. Carlson KM, Bracamontes J, Jackson CE, et al. Parent of origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet. 1994;55:1076-1082.
7. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
8. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet. 1994;3:237-241.
9. Learoyd DL, Twigg SM, Marsh DJ, Robinson BG. The practical management of multiple endocrine neoplasia. Trends Endocrinol Metab. 1995,6:273-278.
10. Marsh DJ, Robinson BG, Andrew S, et al. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics. 1994;23: 477-479.
11. Ward JL, Hyland VJ, Andrew DS, Marsh DJ, Robinson BG. Medullary thyroid carcinoma: Australian experience with genetic testing. Henry Ford Hosp Med J. 1992; 40:220-223.
12. Wells SA Jr, Chi D, Toshima K, Norton JA, Moley JF, Donis-Keller H. Prophylactic thyroidectomy for multiple endocrine neoplasia type 2A. Presented at the Fifth International Workshop on Multiple Endocrine Neoplasia; July 1, 1994; Stockholm, Sweden. Abstract 703.
13. Albores-Saavedra J, Monforte H, Nadji M, Morales AR. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988;19:795-799.
14. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828-835.
15. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW. Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery. 1995;118:257-264.
16. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol. 1991;7:92-99.
17. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 1995;5:407-424.
18. Ponder BA, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet. 1988;1:397-401.
19. Marsh DJ, McDowall D, Hyland VJ, et al. The identification of false-positive responses to the pentagastrin stimulation test in Ret mutation negative members of MEN 2A families. Clin Endocrinol. 1996;44:249-257.
20. Landsvater RM, Rombouts AG, te Meerman GJ, et al. The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN 2A kindred. Am J Hum Genet. 1993;52:335-342.
21. Gibson WGH, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol. 1982;106:388-393.
22. Emmertsen K, Erno H, Henriques U, Schroder HD. C-cells for differentiation between familial and sporadic medullary thyroid carcinoma. Dan Med Bull. 1983; 30:353-356.
23. Khadra M, Delbridge L, Reeve TS, Poole AG, Crummer P. Total thyroidectomy: its role in the management of thyroid disease. Aust N Z J Surg. 1992;62:87-89.
24. Blackburn GL, Giardiello FM. Developing strategies for intervention/prevention trials of individuals at risk of hereditary colon cancer. J Natl Cancer Inst. 1995; 17:107-110.
25. Serova O, Montagna M, Torchard D, et al. A high incidence of BRCA 1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet. 1996;58:42-51.
26. Petersen GM. Knowledge of the Adenomatous Polyposis Coli gene and its clinical application. Ann Med. 1994;26:205-208.
27. Wells SA Jr, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metab Clin North Am. 1994;23:215-228.